



13
Dmt
10-10-02

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 07 2002

TECH CENTER 1600/2900

In re Application of:

Khan et al.

Serial No.: 09/716,777

Filed: November 20, 2000

For: IMMUNOREGULATOR

Confirmation No.: 9134

Examiner: J. Witz

Group Art Unit: 1651

Attorney Docket No.: 2183-4618US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

September 27, 2002
Date

Signature

Betty Vowles
Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

10/03/2002 TBESHAH1 00000004 09716777

01 FC:126

180.00 OP

Serial No.: 09/716,777

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
WO 97/49721	12-31-1997	University of Maryland

Other Documents

PCT International Search Report, PCT/NL01/00259, dated December 18, 2001, 3 pages.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56 & 1.175, applicant hereby identifies the following listed copending applications naming the same inventor(s):

Attorney Docket No.: 2183-4799US
Serial No.: 09/821,380
Filing Date: 3/29/2001
For: IMMUNOREGULATOR

Attorney Docket No.: 2183-5222US
Serial No.: 10/029,206
Filing Date: 12/21/2001
For: OLIGOPEPTIDE TREATMENT OF ANTHRAX

Attorney Docket No.: 2183-5223US
Serial No.: 10/028,075
Filing Date: 12/21/2001
For: GENE REGULATOR

Serial No.: 09/716,777

This Supplemental Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits. The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,



G. Scott Dorland
Registration No. 51,622
Agent for Applicant(s)
TRASKBRITT, PC
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: September 27, 2002

GSD/bv

Enclosures: Form PTO-1449 or PTO/SB/08

Cited Documents

Document in ProLaw